Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Cancers
•
Medical Oncology
What factors into your decision about whether to use HIPEC for advanced ovarian cancer?
Related Questions
For a patient with IIIC1 (micromets), MSI-high, Grade 2 endometrial adenocarcinoma who has undergone full surgical staging, do you recommend adding immunotherapy to adjuvant chemotherapy + radiation?
How do you counsel patients and partners of patients with HPV+ cancers regarding the HPV vaccine?
How would you palliate a large, symptomatic vaginal melanoma recurrence with limited small pelvic lymph node metastases?
Would you add olaparib to maintenance immunotherapy for a patient with recurrent MMR-proficient, HER2-negative serous endometrial carcinoma?
Do you screen for immune-related adrenal insufficiency for patients on immune checkpoint inhibitors?
How would you manage a cervical cancer patient with bulky PA LNs with direct extension and/or invasion into the lumbar vertebral bodies?
Do you recommend concurrent cisplatin and gemcitabine with radiotherapy for unresectable vulvar cancer, as described in GOG-279?
Do you have a maximal limit to the number of pegylated doxorubicin cycles you will prescribe a patient for recurrent endometrial cancer?
For a patient with high-risk metastatic endometrial cancer treated with neoadjuvant chemotherapy followed by surgery, would you offer adjuvant therapy if there is evidence of residual disease?
Would you add dostarlimab to adjuvant carboplatin/paclitaxel in a patient with completely resected IIIA uterine carcinosarcoma (MSI-H)?